HWM
TLSI icon

HighMark Wealth Management’s TriSalus Life Sciences TLSI Stock Holding History

HighMark Wealth Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
33,300
+22,500
+208% +$110K 0.05% 95
2025
Q4 		$75.4K Buy
+10,800
New +$60.5K 0.03% 126

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

HighMark Wealth Management's TLSI Position: Q1 2026 in Review

HighMark Wealth Management increased its TriSalus Life Sciences (TLSI) stake by 208% in Q1 2026, buying an estimated $110K and bringing the position to 33,300 shares worth $133K. The position accounts for 0.05% of the portfolio, ranked #95.

HighMark Wealth Management first reported a position in TLSI in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

  • HighMark Wealth Management held 33,300 shares of TriSalus Life Sciences worth $133K as of Q1 2026.
  • HighMark Wealth Management bought 22,500 TriSalus Life Sciences shares in Q1 2026, an estimated $110K.
  • TriSalus Life Sciences made up 0.05% of HighMark Wealth Management's portfolio in Q1 2026, its #95 holding.
  • HighMark Wealth Management first reported a position in TriSalus Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.